The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer
Open accessAbstract
Learning Objectives: After completing this course, the reader will be able to: Assess the strengths and weaknesses of the four main techniques used to measure multiple gene expression using clinical breast cancer specimens.Compare the advantages and disadvantages of the oncotype DX™ and MammaPrint® multigene assays and compare the TAILORx and MINDACT clinical trials for the prediction of clinical outcome in breast cancer.Evaluate the costs versus benefits associated with the use of expensive multigene breast cancer predictors in the management of breast cancer. CME This article is available for continuing medical education credit at CME.TheOncologist.com In the past 5 years, a number of commercialized multigene prognostic and predictive tests have entered the complex and expanding landscape of breast cancer companion diagnostics. These tests have used a variety of formats ranging from the familiar slide-based assays of immunohistochemistry and fluorescence in situ hybridization to the nonmorphology-driven molecular platforms of quantitative multiplex real-time polymerase chain reaction and genomic microarray profiling. In this review, 14 multigene assays are evaluated as to their scientific validation, current clinical utility, regulatory approval status, and estimated cost–benefit ratio. Emphasis is placed on two tests: oncotype DX™ and MammaPrint®. Current evidence indicates that the oncotype DX™ test has the advantages of earlier commercial launch, wide acceptance for payment by third-party payors in the U.S., ease of use of formalin-fixed paraffin-embedded tissues, recent listing by the American Society of Clinical Oncology Breast Cancer Tumor Markers Update Committee as recommended for use, continuous scoring system algorithm, ability to serve as both a prognostic test and predictive test for certain hormonal and chemotherapeutic agents, demonstrated cost-effectiveness in one published study, and a high accrual rate for the prospective validation clinical trial (Trial Assigning Individualized Options for Treatment). The MammaPrint® assay has the advantages of a 510(k) clearance by the U.S. Food and Drug Administration, a larger gene number, which may enhance further utility, and a potentially wider patient eligibility, including lymph node–positive, estrogen receptor (ER)-negative, and younger patients being accrued into the prospective trial (Microarray in Node-Negative Disease May Avoid Chemotherapy). A number of other assays have specific predictive goals that are most often focused on the efficacy of tamoxifen in ER-positive patients, such as the two-gene ratio test and the cytochrome P450 CYP2D6 genotyping assay.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4147 · Cited by 2,892
Self-citationGene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
Wang, Y., Klijn, J. G., Zhang, Y., Sieuwerts, A. M., Look, M. P., Yang, F., Talantov, D., Timmermans, M., Meijer-van Gelder, M. E., Yu, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17947-1 · Cited by 2,846
Nielsen, T. O., Hsu, F. D., Jensen, K., Cheang, M., Karaca, G., Hu, Z., Hernandez-Boussard, T., Livasy, C., Cowan, D., Dressler, L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0220 · Cited by 2,663
Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W., Cronin, M., Baehner, F. L., Watson, D., Bryant, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7985 · Cited by 2,579
Quantification of mRNA using real-time RT-PCR
Nolan, T., Hands, R. E., & Bustin, S. A. (2006) · Nature Protocols · doi:10.1038/nprot.2006.236 · Cited by 2,247
Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2364 · Cited by 2,217
MAQC Consortium, Shi, L., Shi, L., Reid, L. H., Jones, W. D., Shippy, R., Warrington, J. A., Baker, S. C., Collins, P. J., de Longueville, F., et al. (2006) · Nature Biotechnology · doi:10.1038/nbt1239 · Cited by 2,126
Self-citationThe Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
Carey, L. A., Dees, E. C., Sawyer, L., Gatti, L., Moore, D. T., Collichio, F., Ollila, D. W., Sartor, C. I., Graham, M. L., & Perou, C. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1109 · Cited by 2,087
Sotiriou, C., Wirapati, P., Loi, S., Harris, A., Fox, S., Smeds, J., Nordgren, H., Farmer, P., Praz, V., Haibe-Kains, B., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj052 · Cited by 2,063
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N., Cristofanilli, M., Anderson, K., Hess, K. R., Stec, J., Ayers, M., Wagner, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2421 · Cited by 1,891
Self-citationThe molecular portraits of breast tumors are conserved across microarray platforms
Hu, Z., Fan, C., Oh, D. S., Marron, J., He, X., Qaqish, B. F., Livasy, C., Carey, L. A., Reynolds, E., Dressler, L., et al. (2006) · BMC Genomics · doi:10.1186/1471-2164-7-96 · Cited by 1,491
Concordance among Gene-Expression–Based Predictors for Breast Cancer
Fan, C., Oh, D. S., Wessels, L., Weigelt, B., Nuyten, D. S. A., Nobel, A. B., van't Veer, L. J., & Perou, C. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052933 · Cited by 1,341
Buyse, M., Loi, S., van't Veer, L., Viale, G., Delorenzi, M., Glas, A. M., Saghatchian d'Assignies, M., Bergh, J., Lidereau, R., Ellis, P., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj329 · Cited by 1,238
Ravdin, P. M., Siminoff, L. A., Davis, G. J., Mercer, M. B., Hewlett, J., Gerson, N., & Parker, H. L. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.980 · Cited by 996
The Prognostic Role of a Gene Signature from Tumorigenic Breast-Cancer Cells
Liu, R., Wang, X., Chen, G. Y., Dalerba, P., Gurney, A., Hoey, T., Sherlock, G., Lewicki, J., Shedden, K., & Clarke, M. F. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063994 · Cited by 985
Desmedt, C., Piette, F., Loi, S., Wang, Y., Lallemand, F., Haibe-Kains, B., Viale, G., Delorenzi, M., Zhang, Y., d'Assignies, M. S., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2765 · Cited by 968
Ma, X.-J., Wang, Z., Ryan, P. D., Isakoff, S. J., Barmettler, A., Fuller, A., Muir, B., Mohapatra, G., Salunga, R., Tuggle, J. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.05.015 · Cited by 954
Jin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K.-H., Skaar, T., Storniolo, A. M., Li, L., Araba, A., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji005 · Cited by 951
Chang, J. C., Wooten, E. C., Tsimelzon, A., Hilsenbeck, S. G., Gutierrez, M. C., Elledge, R., Mohsin, S., Osborne, C. K., Chamness, G. C., Allred, D. C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14023-8 · Cited by 875
Loi, S., Haibe-Kains, B., Desmedt, C., Lallemand, F., Tutt, A. M., Gillet, C., Ellis, P., Harris, A., Bergh, J., Foekens, J. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.1522 · Cited by 837
Goetz, M. P., Rae, J. M., Suman, V. J., Safgren, S. L., Ames, M. M., Visscher, D. W., Reynolds, C., Couch, F. J., Lingle, W. L., Flockhart, D. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.3266 · Cited by 791
Hess, K. R., Anderson, K., Symmans, W. F., Valero, V., Ibrahim, N., Mejia, J. A., Booser, D., Theriault, R. L., Buzdar, A. U., Dempsey, P. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.6861 · Cited by 721
Self-citationKreike, B., van Kouwenhove, M., Horlings, H., Weigelt, B., Peterse, H., Bartelink, H., & van de Vijver, M. J. (2007) · Breast Cancer Research · doi:10.1186/bcr1771 · Cited by 613
Ayers, M., Symmans, W. F., Stec, J., Damokosh, A. I., Clark, E., Hess, K., Lecocke, M., Metivier, J., Booser, D., Ibrahim, N., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.166 · Cited by 566 · cited 1×
“One gene set (30 genes) predicts complete response to preoperative paclitaxel, 5-fluorouracil, doxorubicin, and cyclophosphamide (TFAC) chemotherapy and the other (200 genes) predicts outcome after 5 years of endocrine therapy [ 42 ,43].Thisprogramalsoidentifiedtheoverexpressionof mRNAofthebiomarkermicrotubule-associa…”
BackgroundSelf-citationThe impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen
Goetz, M. P., Knox, S. K., Suman, V. J., Rae, J. M., Safgren, S. L., Ames, M. M., Visscher, D. W., Reynolds, C., Couch, F. J., Lingle, W. L., et al. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9428-0 · Cited by 552
Habel, L. A., Shak, S., Jacobs, M. K., Capra, A., Alexander, C., Pho, M., Baker, J., Walker, M., Watson, D., Hackett, J., et al. (2006) · Breast Cancer Research · doi:10.1186/bcr1412 · Cited by 484
Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer
Rouzier, R., Rajan, R., Wagner, P., Hess, K. R., Gold, D. L., Stec, J., Ayers, M., Ross, J. S., Zhang, P., Buchholz, T. A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408974102 · Cited by 413
Self-citationPrognostic value of proliferation in invasive breast cancer: a review: Table 1
van Diest, P. J., van der Wall, E., & Baak, J. P. A. (2004) · Journal of Clinical Pathology · doi:10.1136/jcp.2003.010777 · Cited by 385
Foekens, J. A., Atkins, D., Zhang, Y., Sweep, F. C. G. J., Harbeck, N., Paradiso, A., Cufer, T., Sieuwerts, A. M., Talantov, D., Span, P. N., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.9115 · Cited by 361
Cronin, M., Sangli, C., Liu, M.-L., Pho, M., Dutta, D., Nguyen, A., Jeong, J., Wu, J., Langone, K. C., & Watson, D. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2006.076497 · Cited by 343
Weigelt, B., Hu, Z., He, X., Livasy, C., Carey, L. A., Ewend, M. G., Glas, A. M., Perou, C. M., & van't Veer, L. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2553 · Cited by 332
Rouzier, R., Pusztai, L., Delaloge, S., Gonzalez-Angulo, A. M., Andre, F., Hess, K. R., Buzdar, A. U., Garbay, J.-R., Spielmann, M., Mathieu, M.-C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.2898 · Cited by 286
Self-citationTAILORx: Trial Assigning Individualized Options for Treatment (Rx)
Sparano, J. A. (2006) · Clinical Breast Cancer · doi:10.3816/cbc.2006.n.051 · Cited by 262
The HOXB13:IL17BR Expression Index Is a Prognostic Factor in Early-Stage Breast Cancer
Ma, X.-J., Hilsenbeck, S. G., Wang, W., Ding, L., Sgroi, D. C., Bender, R. A., Osborne, C. K., Allred, D. C., & Erlander, M. G. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.6944 · Cited by 252
Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial
Bogaerts, J., Cardoso, F., Buyse, M., Braga, S., Loi, S., Harrison, J. A., Bines, J., Mook, S., Decker, N., Ravdin, P., et al. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0591 · Cited by 237
Tumor Gene Expression and Prognosis in Breast Cancer Patients with 10 or More Positive Lymph Nodes
Cobleigh, M. A., Tabesh, B., Bitterman, P., Baker, J., Cronin, M., Liu, M.-L., Borchik, R., Mosquera, J.-M., Walker, M. G., & Shak, S. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0735 · Cited by 232
Perreard, L., Fan, C., Quackenbush, J. F., Mullins, M., Gauthier, N. P., Nelson, E., Mone, M., Hansen, H., Buys, S. S., Rasmussen, K., et al. (2006) · Breast Cancer Research · doi:10.1186/bcr1399 · Cited by 205
Chang, J. C., Wooten, E. C., Tsimelzon, A., Hilsenbeck, S. G., Gutierrez, M. C., Tham, Y.-L., Kalidas, M., Elledge, R., Mohsin, S., Osborne, C. K., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.156 · Cited by 197
Gong, Y., Yan, K., Lin, F., Anderson, K., Sotiriou, C., Andre, F., Holmes, F. A., Valero, V., Booser, D., Pippen, J. E., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70042-6 · Cited by 195
Self-citationExpression profiling predicts outcome in breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A., Bernards, R., & Friend, S. H. (2002) · Breast Cancer Research · doi:10.1186/bcr562 · Cited by 181
Novel Prognostic Immunohistochemical Biomarker Panel for Estrogen Receptor–Positive Breast Cancer
Ring, B. Z., Seitz, R. S., Beck, R., Shasteen, W. J., Tarr, S. M., Cheang, M. C. U., Yoder, B. J., Budd, G. T., Nielsen, T. O., Hicks, D. G., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.6564 · Cited by 181
Are clusters found in one dataset present in another dataset?
Kapp, A. V., & Tibshirani, R. (2007) · Biostatistics · doi:10.1093/biostatistics/kxj029 · Cited by 181
Lyman, G. H., Cosler, L. E., Kuderer, N. M., & Hornberger, J. (2007) · Cancer · doi:10.1002/cncr.22506 · Cited by 179
Paik, S. (2007) · The Oncologist · doi:10.1634/theoncologist.12-6-631 · Cited by 177
Gene expression profiling of primary breast carcinomas using arrays of candidate genes
Bertucci, F. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.20.2981 · Cited by 175
Symmans, W. F., Ayers, M., Clark, E. A., Stec, J., Hess, K. R., Sneige, N., Buchholz, T. A., Krishnamurthy, S., Ibrahim, N. K., Buzdar, A. U., et al. (2003) · Cancer · doi:10.1002/cncr.11435 · Cited by 174
Self-citationGoetz, M. P., Suman, V. J., Ingle, J. N., Nibbe, A. M., Visscher, D. W., Reynolds, C. A., Lingle, W. L., Erlander, M., Ma, X.-J., Sgroi, D. C., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1263 · Cited by 170
Esteva, F. J., Sahin, A. A., Cristofanilli, M., Coombes, K., Lee, S.-J., Baker, J., Cronin, M., Walker, M., Watson, D., Shak, S., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1707 · Cited by 168
Henry, N. L., & Hayes, D. F. (2006) · The Oncologist · doi:10.1634/theoncologist.11-6-541 · Cited by 149
Is Molecular Profiling Ready for Use in Clinical Decision Making?
Ioannidis, J. P. A. (2007) · The Oncologist · doi:10.1634/theoncologist.12-3-301 · Cited by 137
Cleator, S. J., Tsimelzon, A. I., Ashworth, A., Dowsett, M., Dexter, T., Powles, T. J., Hilsenbeck, S. G., Wong, H. H., Osborne, C. K., O'Connell, P., et al. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9009-7 · Cited by 129
Discovery and validation of breast cancer subtypes
Kapp, A. V., Jeffrey, S. S., Langerød, A., Børresen‐Dale, A., Han, W., Noh, D., Bukholm, I. R., Nicolau, M. M., Brown, P. O., & Tibshirani, R. J. (2006) · BMC Genomics · doi:10.1186/1471-2164-7-231 · Cited by 129
André, F., Hatzis, C., Anderson, K., Sotiriou, C. P., Mazouni, C., Mejia, J. A., Wang, B., Hortobágyi, G. N., Symmans, W. F., & Pusztai, L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2078 · Cited by 128
Self-citationPathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer
Yu, J. X., Sieuwerts, A. M., Zhang, Y., Martens, J. W. M., Smid, M., Klijn, J. G. M., Wang, Y., & Foekens, J. A. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-182 · Cited by 121
Breast cancer biomarkers and molecular medicine
Ross, J. S., Linette, G. P., Stec, J. J., Clark, E. A., Ayers, M., Leschly, N., Symmans, W. F., Hortobágyi, G. N., & Pusztai, L. (2003) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.3.5.573 · Cited by 113
Self-citationThe Prognostic Biomarkers HOXB13, IL17BR, and CHDH Are Regulated by Estrogen in Breast Cancer
Wang, Z., Dahiya, S. M., Provencher, H. L., Muir, B., Carney, E., Coser, K. R., Shioda, T., Ma, X., & Sgroi, D. C. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0310 · Cited by 107
Molecular profiling of breast cancer: clinical implications
Cleator, S. J., & Ashworth, A. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601667 · Cited by 98
Wagner, P., Wang, B., Clark, E. A., Lee, H., Rouzier, R., & Pusztai, L. (2005) · Cell Cycle · doi:10.4161/cc.4.9.2038 · Cited by 80
Self-citationMullins, M., Perreard, L., Quackenbush, J. F., Gauthier, N. P., Bayer, S., Ellis, M. J., Parker, J. S., Perou, C. M., Szabó, A., & Bernard, P. S. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2006.083725 · Cited by 73
Stec, J. J., Wang, J., Coombes, K. R., Ayers, M., Hoersch, S., Gold, D. L., Ross, J. S., Hess, K. R., Tirrell, S. M., Linette, G. P., et al. (2005) · Journal of Molecular Diagnostics · doi:10.1016/s1525-1578(10)60565-x · Cited by 52
Self-citationAmplification Patterns of Three Genomic Regions Predict Distant Recurrence in Breast Carcinoma
Davis, L. M., Harris, C., Tang, L., Doherty, P., Hraber, P., Sakai, Y., Bocklage, T. J., Doeden, K., Hall, B., Alsobrook, J. P., et al. (2007) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2007.060079 · Cited by 50
Microarrays in breast cancer research and clinical practice – the future lies ahead
Gruvberger-Saal, S. K., Cunliffe, H. E., Carr, K. M., & Hedenfalk, I. A. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01246 · Cited by 31
Ross, J. S., Symmans, W. F., Pusztai, L., & Hortobágyi, G. N. (2005) · Advances in clinical chemistry · doi:10.1016/s0065-2423(05)40003-7 · Cited by 27
Self-citationPeintinger, F., Anderson, K., Mazouni, C., Kuerer, H. M., Hatzis, C., Lin, F., Hortobágyi, G. N., Symmans, W. F., & Pusztai, L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2600 · Cited by 26
Self-citationGene Expression Signatures to Predict the Development of Metastasis in Breast Cancer
Nuyten, D. S. A., & van de Vijver, M. J. (2007) · Breast Disease · doi:10.3233/bd-2007-26113 · Cited by 18
Cited by
Gene-Expression Signatures in Breast Cancer
Sotiriou, C., & Pusztai, L. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0801289 · Cited by 1,485
Self-citationRoss, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobagyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,144
Self-citationWeigelt, B., Baehner, F. L., & Reis‐Filho, J. S. (2010) · The Journal of Pathology · doi:10.1002/path.2648 · Cited by 482
Histological, molecular and functional subtypes of breast cancers
Malhotra, G. K., Zhao, X., Band, H., & Band, V. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.10.13879 · Cited by 475
Lowery, A. J., Miller, N., Devaney, A., McNeill, R. E., Davoren, P. A., Lemetre, C., Benes, V., Schmidt, S., Blake, J., Ball, G., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2257 · Cited by 450
Metadata
- Authors
- Ross, J. S., Hatzis, C., Symmans, W. F., Pusztai, L., & Hortobágyi, G. N.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-05-01
- Volume
- 13
- Issue
- 5
- Pages
- 477-493
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2038103024
- Cited by
- 259
- References
- 70
- FWCI
- 11.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.